[Alcohol withdrawal syndrome dynamics during treatment with nooclerin (deanoli aceglumas)].

Autor:	Agibalova TV; Research Center for Substance Use Disorders, Moscow, Russia; Russian University for Friendship, Moscow, Russia., Buzik OZ; Research Center for Substance Use Disorders, Moscow, Russia., Rychkova OV; Federal Medical Research Center for Psychiatry and Narcology, Moscow, Russia., Smyshlyaev AV; Central Scientific Research Institute of Health Organization and Informatization, Moscow, Russia., Rumbesht VV; Belgorod State National Research University, Belgorod, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2018; Vol. 118 (1. Vyp. 2), pp. 45-51.
DOI:	10.17116/jnevro20181181245-51
Abstrakt:	Aim: To study the efficacy of nooclerin (deanoli aceglumas) in alcohol withdrawal syndrome assessed by clinical and biochemical characteristics. Material and Methods: A multicenter, open, randomized, comparative study of nooclerin in the complex treatment of alcohol withdrawal syndrome included 90 patients. The patients were randomized into nooclerin group (n=55) and control group (n=35). Results and Conclusion: Nooclerin reduced alcohol withdrawal symptoms more significantly throughout the whole study period. There were significant between-group differences on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) and the Multidimensional Fatigue Inventory (МFI-20). However, patients exhibited no excessive activity. No adverse side-effects were observed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu